Skip to main content
×
×
Home

Audit of combination and high-dose antipsychotic treatment in the community

  • Lovely Rajan (a1) and Ian Clarke (a1)
Abstract
Aims and method

To estimate the community prevalence of combination antipsychotic therapy and high-dose antipsychotic treatment via audit. Patients with an ICD-10 diagnosis of schizophrenia were identified through the NHS Greater Glasgow and Clyde Health Board patient information management system and their mental health records examined.

Results

In audit 1, 135 records were examined. The age range of patients was 24–74 years; 73% were male. Twelve per cent were on combined antipsychotic treatment and 3.7% required high-dose antipsychotics. Sixty-nine per cent of patients had documented in their record the reason for combined antipsychotic treatment compared with 40% on high-dose antipsychotics. In audit 2 (1 year later), 150 records were examined. Demographic details and prescription patterns remained similar to that of audit 1. However, 10% of patients received combined antipsychotic therapy and 2% remained on high-dose antipsychotics. Documented reasons for combination therapy increased to 87%, and to 67% for patients on high-dose antipsychotics.

Clinical implications

We need robust clinical trials, overcoming the problems of clinical effectiveness and clinical efficiency, to establish the merits of preferred antipsychotic combinations, as combination and high-dose antipsychotic treatments are unlikely to be eliminated in clinical practice in the foreseeable future.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Audit of combination and high-dose antipsychotic treatment in the community
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Audit of combination and high-dose antipsychotic treatment in the community
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Audit of combination and high-dose antipsychotic treatment in the community
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Lovely Rajan (lovely.rajan@nhs.net)
Footnotes
Hide All

Declaration of interest

L.R. was a specialty doctor at Arndale Mental Health Resource Centre at the time of the study and I.C. is one of two consultants based at Arndale Mental Health Resource Centre.

Footnotes
References
Hide All
1 Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication (Council Report CR138). Royal College of Psychiatrists, 2006.
2 Harrington, M, Lelliott, C, Paton, C, Okocha, C, Duffett, R, Sensky, T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull 2002; 26: 414–8.
3 Keks, NA, Alston, K, Hope, J, Krapivensky, N, Culhane, C, Tanaghow, A, et al. Use of antipsychotics and adjunctive medications by inner urban community psychiatric service. Aust N Z J Psychiatry 1999; 33: 896901.
4 Ito, C, Kubota, Y, Sato, M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 (suppl): S3540.
5 Ito, H, Koyama, A, Higuchi, T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005; 187: 243–7.
6 Taylor, M, Shajahan, P, Lawrie, SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008; 69: 240–5.
7 Tungaraza, TE, Gupta, S, Jones, J, Poole, R, Slegg, G. Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist 2010; 34: 44–6.
8 Grech, P, Taylor, D. Long-term antipsychotic polypharmacy: how does it start, why does it continue? Therapeutic Advances in Psychopharmacology 2012; 2: 511.
9 Taylor, D. Antipsychotic polypharmacy – confusion reigns. Psychiatrist 2010; 34: 41–3.
10 Fleischhacker, WW, Heikkinen, T, Olie, JP, Landsberg, W, Dwaele, P, McQuade, RD, et al. Weight change on aripiprazole–clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry 2008; 2 (suppl 23): s1145.
11 Shim, JC, Shin, JG, Kelly, DL, Jung, DU, Seo, YS, Liu, KH et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo controlled trail. Am J Psychiatry 2007; 164: 1404–10.
12 Josiassen, RC, Joseph, A, Kohegyi, E, Stokes, S, Dadvand, M, Paing, WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomised, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130–6.
13 Shiloh, R, Zemishlany, Z, Aizenberg, D, Radwan, M, Schwartz, B, Dorfman-Etrog, P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569–73.
14 Langan, J, Shajahan, P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 2010; 34: 5862.
15 National Collaborating Centre for Mental Health. Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition). British Psychological Society and Royal College of Psychiatrists, 2010.
16 Royal Pharmaceutical Society of Great Britain, British Medical Association. British National Formulary 56. BMJ Books & Pharmaceuticals Press, 2008.
17 Taylor, D, Paton, C, Kapur, S. The Maudsley Prescribing Guidelines (10th edn). Informa Healthcare, 2009.
18 NHS Greater Glasgow and Clyde Health Board. High Dose Antipsychotic Therapy Guideline. NHS Greater Glasgow and Clyde, 2008.
19 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
20 Yorston, G, Pinney, A. Use of high dose antipsychotic medication. Psychiatr Bull 1997; 21: 566–9.
21 Hayhurst, K. Pennine Care NHS Trust Antipsychotic Prescribing Audit. The University of Manchester, 2006 (http://www.south.manchester.ac.uk/psychiatry/capri/documents/PennineCareAntipsychoticPrescribingAudit2005.pdf).
22 NHS Quality Improvement Scotland. Standards for Integrated Care Pathways for Mental Health. NHS Quality Improvement Scotland, 2007.
23 Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481–5.
24 Paton, C, Barnes, TRE, Cavanagh, M-R, Taylor, D, Lelliott, P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n prescribing. Br J Psychiatry 2008; 192: 435–9.
25 Tyson, PJ, Mortimer, AM, Wheeler, JA. High-dose antipsychotic treatment in clinical practice. A review, audit and survey of consultant psychiatrist opinions. Psychiatr Bull 1999; 23: 661–4.
26 Geddes, JR, Freemantle, N, Harrison, P, Bebbington, PE. Atypical antipsychotics in the treatment of schizophrenia – systematic review and meta-regression analysis. BMJ 2000; 321: 1371–6.
27 Waddington, JL, Youssef, HA, Kinsella, A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9.
28 Curkendall, SM, Mo, J, Glasser, DB, Rose Stang, M, Jones, JK. Cardiovascular disease in patients with schizophrenia in Saskatchwan, Canada. J Clin Psychiatry 2004; 65: 715–20.
29 Barnes, TRE, Paton, C. Role of the Prescribing Observatory for Mental Heath. Br J Psychiatry 2012; 201: 428–9.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 1758-3209
  • EISSN: 1758-3217
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 2
Total number of PDF views: 11 *
Loading metrics...

Abstract views

Total abstract views: 106 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 23rd July 2018. This data will be updated every 24 hours.

Audit of combination and high-dose antipsychotic treatment in the community

  • Lovely Rajan (a1) and Ian Clarke (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *